Iron-based MRI agent detects and slows heart scarring in lab-grown human tissue

Scientists have created an iron-based contrast agent for magnetic resonance imaging (MRI) that can be used for both diagnosis and treatment of cardiac fibrosis, a condition that leads to heart failure. The study, conducted by researchers from the Biomolecular Nanotechnology group at Ikerbasque and the Institute of Biomedicine and Biotechnology of Cantabria, was published in Advanced Functional Materials.

In laboratory tests on human heart tissue, the new contrast agent was shown to accumulate in fibrotic tissue, with signal intensity on the MRI image increasing as the severity of the disease progressed. Importantly, the agent slowed the progression of the disease by reducing the production and storage of collagen, which contributes to tissue stiffness.

This theranostic agent, which combines diagnostic and therapeutic properties in a single material, has the potential to offer a safer alternative to existing gadolinium-based contrast agents used in almost all MRI scans. Gadolinium, while effective, poses risks for patients with kidney failure and those requiring repeated scans. The iron-based agent, on the other hand, is safer, more stable, and easier to produce without toxic reagents or extreme conditions.

Further research will be needed to determine the agent's suitability for clinical use, including its distribution, elimination from the body, and performance on real cardiac scanners. If successful, this new therapy could provide a safer and more effective imaging test for patients with cardiac fibrosis, particularly those who cannot receive gadolinium-based contrast agents.